The decision is driven by recent findings derived from a non-interventional human study utilizing a clinically validated CANscript platform. GBR 1342 is based on Glenmark’s proprietary BEAT® platform
The post Glenmark Pharmaceuticals plans to launch phase 1 trial in solid tumors appeared first on Pharma Business review.
Original Article: Glenmark Pharmaceuticals plans to launch phase 1 trial in solid tumors